Skip to content

Comparison of Two Apical Repair Methods in Women Undergoing Repairs for Prolapse

Randomized Trial of Sacrospinous Ligament Fixation Versus McCall Culdoplasty in Women Undergoing Vaginal Hysterectomy and Repairs for Prolapse

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03113513
Enrollment
312
Registered
2017-04-13
Start date
2016-05-01
Completion date
2025-04-30
Last updated
2024-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complication, Pelvic Organ Prolapse, Quality of Life, Surgery

Brief summary

To date no study has determined prospectively which technique is superior to prevent recurrent Pelvic Organ Prolapse (POP) after vaginal hysterectomy- a major unmet clinical need. The aim of the study is to determine objective anatomical recurrent prolapse after Sacrospinous Ligament Fixation (SLF) vs McCall.

Detailed description

The aim of the study is to determine objective anatomical recurrent prolapse after SLF vs McCall. The study is designed as a Randomized Controlled Trial (RCT). Primary study endpoint will be at 12 months, secondary study endpoint at 24 months. The following parameters will be evaluated after one year: anatomical outcome, Quality of Life (QoL), sexual health, reoperations, and complications.

Interventions

PROCEDUREfixation of the vaginal apex

In the course of vaginal hysterectomy the vaginal cuff is either fixed to the sacrospinous ligament or to the uterosacral ligament.

Sponsors

Medical University of Graz
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

The study is designed as a RCT.

Eligibility

Sex/Gender
FEMALE
Age
35 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* declined/ failed conservative treatment for POP * planned vaginal hysterectomy with anterior/posterior colporrhaphy as indicated * any symptomatic POP or stage II prolapse in any compartment * at least stage I prolapse in the apical department * women between 35 and 80 years of age * good German language skills * any concomitant prolapse surgery (anterior, posterior vaginal repair, suburethral tapes) as indicated * concomitant salpingo-oophorectomy if indicated

Exclusion criteria

* Unwillingness to participate * Neurological disorders * Previous hysterectomy * Desire to have children * Connective tissue disorders (i.e. Ehlers-Danlos syndrome, Marfan syndrome)

Design outcomes

Primary

MeasureTime frameDescription
Number of patients with stage 2 or higher on the Pelvic Organ Prolapse Quantification System (POP-Q).12 months after surgeryPOP-Q stage 2 or higher means any point of the POP-Q system being -1 related to the hymen or below

Secondary

MeasureTime frameDescription
Subjective cure12 months after surgerydetermined by the Patient Global Impression of Improvement (PGII) index
Quality of life as determined by a questionnaire12 months after surgeryThe Kings Health Questionnaire was validated in women with stress urinary incontinence and assesses the impact of incontinence on quality of life. The eight subscales (domains) scored between 0 (best) and 100 (worst). The Symptom Severity scale is scored from 0 (best) to 30 (worst); lower scores indicate better QoL. Success in terms of the study is defined as 10 points improvement on the total Kings Health Questionnaire score.
Sexual health12 months after surgeryThe Pelvic Organ Prolapse Incontinence Sexual Questionnaire is a 20 item questionnaire and is the primary measure used to assess sexual function in women with urinary incontinence and prolapse. Mean subscale scores are calculated by summing the valid responses to items in the subscale and then divided by the number of items with valid responses. The higher the subscores, the worse the outcome.
Reoperation rate12 months after surgeryNumber of patients with any reoperations for POP

Countries

Austria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026